Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Successful Treatment of Vancomycin-Resistant Enterococcus Bacteremia With a Combination of Daptomycin and Tigecycline in an Infant who Underwent Heart-Lung Transplantation

  • Kang, Jeong Eun (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Byun, Joung-Hee (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Kim, Younga (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Park, Su Eun (Department of Pediatrics, Pusan National University Children's Hospital)
  • Received : 2022.04.05
  • Accepted : 2022.08.18
  • Published : 2022.08.25
Download PDF
⟨ Previous Next ⟩

Abstract

The treatment of invasive infections caused by multidrug-resistant vancomycin-resistant enterococci (VRE) is challenging, particularly in pediatric patients with underlying medical conditions. Newer antibiotics used to treat VRE infections in pediatric patients are insufficiently studied. This report presents the case of a 6-month-old infant who underwent heart-lung transplantation and was successfully treated with a combination of daptomycin and tigecycline for recurrent VRE bacteremia shortly after the discontinuation of linezolid.

다제내성 반코마이신 저항성 장내구균(multidrug-resistant vancomycin-resistant enterococci, VRE)에 의한 침습감염의 치료는 특히 기저질환을 가진 소아 환자들에게 어려운 점이 있다. 소아환자들에게서 VRE 감염을 치료하기 위한 새로운 항생제에 대한 연구가 충분히 이루어지지 않았다. 본 증례는 심폐이식을 받은 생후 6개월 된 영아에서 linezolid 중단 이후 재발된 VRE 균혈증에 대해 daptomycin과 tigecycline 조합으로 성공적으로 치료하여 이를 보고하는 바이다.

Keywords

References

  1. Tamma PD, Hsu AJ. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. Curr Opin Infect Dis 2014;27:517-27. https://doi.org/10.1097/QCO.0000000000000115
  2. Foolad F, Taylor BD, Shelburne SA, Arias CA, Aitken SL. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother 2018;73:2277-83. https://doi.org/10.1093/jac/dky072
  3. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015;8:217-30.
  4. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555-62. https://doi.org/10.1111/j.1469-0691.2010.03214.x
  5. Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646-9. https://doi.org/10.1093/jac/dkh144
  6. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41 Suppl 5:S333-40. https://doi.org/10.1086/431674
  7. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31. https://doi.org/10.1016/S1473-3099(04)01109-0
  8. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, et al. Ampicillin enhances daptomycinand cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012;56:838-44. https://doi.org/10.1128/AAC.05551-11
  9. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014;58:1494-500. https://doi.org/10.1128/AAC.02274-13
  10. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-4. https://doi.org/10.1002/jhm.236
  11. Polidori M, Nuccorini A, Tascini C, Gemignani G, Iapoce R, Leonildi A, et al. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. J Chemother 2011;23:240-1. https://doi.org/10.1179/joc.2011.23.4.240
  12. Munita JM, Mishra NN, Alvarez D, Tran TT, Diaz L, Panesso D, et al. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis 2014;59:1277-80. https://doi.org/10.1093/cid/ciu642